Petros Pharmaceuticals, Inc. Increase (Decrease) in Other Current Liabilities
Petros Pharmaceuticals, Inc. (PTPI) reported Increase (Decrease) in Other Current Liabilities of -$297.88 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-31.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherCurrentLiabilities · last filed 2025-03-31
- Petros Pharmaceuticals, Inc. increase (decrease) in other current liabilities for the quarter ending 2024-12-31 was -$204.26K, a 883.31% decline year-over-year.
- Petros Pharmaceuticals, Inc. increase (decrease) in other current liabilities for the quarter ending 2024-09-30 was -$68.11K, a 197.97% decline year-over-year.
- Petros Pharmaceuticals, Inc. increase (decrease) in other current liabilities for the quarter ending 2024-06-30 was -$11.69K.
- Petros Pharmaceuticals, Inc. increase (decrease) in other current liabilities for the quarter ending 2024-03-31 was -$13.82K, a 139.35% decline year-over-year.
- Petros Pharmaceuticals, Inc. increase (decrease) in other current liabilities for fiscal 2024 was -$297.88K, a 347.84% decline from fiscal 2023.
- Petros Pharmaceuticals, Inc. increase (decrease) in other current liabilities for fiscal 2023 was $120.19K, a 83.86% increase from fiscal 2022.
- Petros Pharmaceuticals, Inc. increase (decrease) in other current liabilities for fiscal 2022 was $65.37K.
- Petros Pharmaceuticals, Inc. increase (decrease) in other current liabilities for fiscal 2021 was -$31.29K.
| Period end | Increase (Decrease) in Other Current Liabilities 3 month | Increase (Decrease) in Other Current Liabilities 6 month | Increase (Decrease) in Other Current Liabilities 9 month | Increase (Decrease) in Other Current Liabilities 12 month |
|---|---|---|---|---|
| 2024-12-31 | -$204.26K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$272.38K derived: sum of 2 quarters · filed 2025-03-31 | -$284.07K derived: sum of 3 quarters · filed 2025-03-31 | -$297.88K 10-K · filed 2025-03-31 |
| 2024-09-30 | -$68.11K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$79.80K derived: sum of 2 quarters · filed 2024-11-13 | -$93.62K 10-Q · filed 2024-11-13 | -$67.54K derived: sum of 4 quarters · filed 2025-03-31 |
| 2024-06-30 | -$11.69K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$25.51K 10-Q · filed 2024-08-14 | $571.00 derived: sum of 3 quarters · filed 2025-03-31 | $70.10K derived: sum of 4 quarters · filed 2025-03-31 |
| 2024-03-31 | -$13.82K 10-Q · filed 2024-05-15 | $12.26K derived: sum of 2 quarters · filed 2025-03-31 | $81.79K derived: sum of 3 quarters · filed 2025-03-31 | $71.26K derived: sum of 4 quarters · filed 2025-03-31 |
| 2023-12-31 | $26.08K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $95.60K derived: sum of 2 quarters · filed 2025-03-31 | $85.08K derived: sum of 3 quarters · filed 2025-03-31 | $120.19K 10-K · filed 2025-03-31 |
| 2023-09-30 | $69.53K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $59.00K derived: sum of 2 quarters · filed 2024-11-13 | $94.11K 10-Q · filed 2024-11-13 | $5.11K derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | -$10.52K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $24.59K 10-Q · filed 2024-08-14 | -$64.42K derived: sum of 3 quarters · filed 2024-08-14 | -$87.59K derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $35.11K 10-Q · filed 2024-05-15 | -$53.89K derived: sum of 2 quarters · filed 2024-05-15 | -$77.07K derived: sum of 3 quarters · filed 2024-05-15 | -$61.48K derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | -$89.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | -$112.18K derived: sum of 2 quarters · filed 2024-04-01 | -$96.59K derived: sum of 3 quarters · filed 2024-04-01 | $65.37K 10-K · filed 2024-04-01 |
| 2022-09-30 | -$23.18K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-15 | -$7.59K derived: sum of 2 quarters · filed 2023-11-15 | $154.37K 10-Q · filed 2023-11-15 | -$234.28K derived: sum of 4 quarters · filed 2023-11-15 |
| 2022-06-30 | $15.59K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $177.55K 10-Q · filed 2023-08-14 | -$211.10K derived: sum of 3 quarters · filed 2023-08-14 | -$40.08K derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $161.96K 10-Q · filed 2023-05-15 | -$226.69K derived: sum of 2 quarters · filed 2023-05-15 | -$55.67K derived: sum of 3 quarters · filed 2023-05-15 | $55.68K derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | -$388.65K derived: 10-K 12 month − 10-Q/A 9 month · filed 2023-03-31 | -$217.63K derived: sum of 2 quarters · filed 2023-03-31 | -$106.28K derived: sum of 3 quarters · filed 2023-03-31 | -$31.29K 10-K · filed 2023-03-31 |
| 2021-09-30 | $171.02K derived: 10-Q/A 9 month − 10-Q 6 month · filed 2022-11-15 | $282.37K derived: sum of 2 quarters · filed 2022-11-15 | $357.36K 10-Q/A · filed 2022-11-15 | -$41.76K derived: sum of 4 quarters · filed 2022-11-15 |
| 2021-06-30 | $111.35K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | $186.34K 10-Q · filed 2022-08-12 | -$212.78K derived: sum of 3 quarters · filed 2022-08-12 | -$165.33K derived: sum of 4 quarters · filed 2022-08-12 |
| 2021-03-31 | $74.99K 10-Q · filed 2022-05-16 | -$324.13K derived: sum of 2 quarters · filed 2022-05-16 | -$276.68K derived: sum of 3 quarters · filed 2022-05-16 | -$271.50K derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | -$399.12K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | -$351.67K derived: sum of 2 quarters · filed 2022-03-31 | -$346.49K derived: sum of 3 quarters · filed 2022-03-31 | -$231.32K 10-K · filed 2022-03-31 |
| 2020-09-30 | $47.45K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $52.63K derived: sum of 2 quarters · filed 2021-11-15 | $167.79K 10-Q · filed 2021-11-15 | |
| 2020-06-30 | $5.18K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | $120.35K 10-Q · filed 2021-08-16 | ||
| 2020-03-31 | $115.17K 10-Q · filed 2021-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B |